Tag: NR

Research Context

The supplied NAD⁺ literature set spans isolated human trials, multiple reviews, and extensive preclinical/mechanistic work focused largely on nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Review and mechanistic papers dominate; direct primary human evidence is sparse and narrowly scoped. The packet explicitly cautions that mechanistic plausibility does not establish clinical utility and that broad anti-aging claims are unsupported by the available human data [pubmed:24786309][pubmed:37424179].

Direct Answer

• Most published NAD⁺ research in this packet is review or preclinical. Direct human evidence exists but is narrow and endpoint-specific [pubmed:37619764][pubmed:29249689][pubmed:35499054][pubmed:37424179].
• One randomized, double-blind, placebo-controlled NMN trial evaluated NAD⁺ metabolism biomarkers and arterial stiffness in a defined population; findings on those endpoints should not be generalized to broad anti-aging or disease-modifying efficacy [pubmed:36797393].
• Dosing parameters and long-term, generalized safety in humans remain incompletely defined in the literature set [pubmed:35499054][pubmed:37068054].

Human Evidence (Direct)

• A randomized, double-blind, placebo-controlled trial assessed the effects of long-term NMN on NAD⁺ metabolism and arterial stiffness. The endpoints and population are specific, and results should not be extrapolated to other outcomes or groups [pubmed:36797393].
• The packet’s clinical claims emphasize that while some human data exist, conclusions must remain anchored to the studied population and endpoints rather than generalized beyond them [pubmed:37619764][pubmed:24786309][pubmed:29249689][pubmed:35499054][pubmed:37424179].

Review Literature (Context, Not Primary Evidence)

These sources synthesize existing data but do not add new primary human outcomes:

• NMN-focused clinical trial updates on safety and anti-aging framing (review-level synthesis) [pubmed:37619764].
• Human-focused overview of NAD⁺-boosting compounds (mixed NMN/NR context, future directions noted) [pubmed:37068054].
• NR-specific review of what is known from human supplementation studies [pubmed:37478182].
• Benefit/risk analysis of NAD⁺ therapy in age-related disorders (conceptual framework) [pubmed:31917996].
• NMN as an anti-aging product: promises and safety concerns (review and commentary) [pubmed:35499054].

Note: Where reviews focus on NMN (e.g., [pubmed:37619764][pubmed:35499054]) versus NR (e.g., [pubmed:37478182]), conclusions should not be cross-extrapolated between compounds without direct supporting data.

Preclinical and Mechanistic Evidence

The packet includes mechanistic and non-human work on:

• NAD⁺ and sirtuin biology in aging and disease [pubmed:24786309][pubmed:30355082].
• The biology and potential of NAD⁺ intermediates NMN and NR [pubmed:29249689].
• In vivo evidence for NAD⁺-boosting molecules in non-human models [pubmed:29514064].
• Roles of NAD metabolism in senescence regulation and aging [pubmed:37424179].
• Potential mechanisms underlying NMN’s actions in aging contexts [pubmed:37548938].

Mechanistic plausibility and non-human in vivo findings do not establish clinical efficacy in humans [pubmed:24786309][pubmed:37424179].

What Is Not Established

• Generalized anti-aging or disease-modifying efficacy in humans is not supported by the packet’s evidence base [pubmed:37619764][pubmed:37424179].
• Cross-compound generalization between NMN and NR lacks direct human support when specific endpoints/populations differ [pubmed:37478182][pubmed:37619764][pubmed:35499054].
• Dosing guidance and long-term, generalized safety remain incompletely defined in humans; the literature advises caution against off-label extrapolation [pubmed:35499054][pubmed:37068054].

References

• [pubmed:36797393] Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/36797393/
• [pubmed:37619764] The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. https://pubmed.ncbi.nlm.nih.gov/37619764/
• [pubmed:24786309] NAD+ and sirtuins in aging and disease. https://pubmed.ncbi.nlm.nih.gov/24786309/
• [pubmed:29249689] NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. https://pubmed.ncbi.nlm.nih.gov/29249689/
• [pubmed:35499054] Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. https://pubmed.ncbi.nlm.nih.gov/35499054/
• [pubmed:37424179] NAD metabolism: Role in senescence regulation and aging. https://pubmed.ncbi.nlm.nih.gov/37424179/
• [pubmed:29514064] Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. https://pubmed.ncbi.nlm.nih.gov/29514064/
• [pubmed:37068054] Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. https://pubmed.ncbi.nlm.nih.gov/37068054/
• [pubmed:37548938] Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging. https://pubmed.ncbi.nlm.nih.gov/37548938/
• [pubmed:37478182] What is really known about the effects of nicotinamide riboside supplementation in humans. https://pubmed.ncbi.nlm.nih.gov/37478182/
• [pubmed:31917996] NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. https://pubmed.ncbi.nlm.nih.gov/31917996/
• [pubmed:30355082] Sirtuins and NAD(+) in the Development and Treatment of Metabolic and Cardiovascular Diseases. https://pubmed.ncbi.nlm.nih.gov/30355082/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.